Trials / Unknown
UnknownNCT02573272
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 204 (estimated)
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eslicarbacepine |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-07-01
- Completion
- 2016-10-01
- First posted
- 2015-10-09
- Last updated
- 2015-10-09
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02573272. Inclusion in this directory is not an endorsement.